BioCanvas
표적 · CD301

CD301 항체

5최다 인용
25인용된 항체
6벤더
Antibody Registry데이터 출처 · RRID CC0

논문 인용순 항체

Antibody Registry 인용수 기준 · 25종
1
BioLegend#145704 (also 145703) RRID:AB_2561961 monoclonal
5
cited by
2
Bio-Rad#MCA2392 RRID:AB_872014 monoclonal
4
cited by
3
BioLegend#354704 (also 354703) RRID:AB_11219002 monoclonal
3
cited by
4
BioLegend#145706 (also 145705) RRID:AB_2562940 monoclonal
2
cited by
5
BioLegend#354706 (also 354705) RRID:AB_11219389 monoclonal
2
cited by
6
Bio-Rad#MCA2392A488 RRID:AB_872011 monoclonal
1
cited by
7
Bio-Rad#MCA2392A647 RRID:AB_872012 monoclonal
1
cited by
8
Bio-Rad#MCA2392A647T RRID:AB_1101873 monoclonal
1
cited by
9
Bio-Rad#MCA2392T RRID:AB_1101876 monoclonal
1
cited by
10
BioLegend#145705 (also 145706) RRID:AB_2562939 monoclonal
1
cited by
11
BioLegend#145708 (also 145707) RRID:AB_2562942 monoclonal
1
cited by
12
BioLegend#145709 (also 145710) RRID:AB_2564578 monoclonal
1
cited by
13
BioLegend#145710 (also 145709) RRID:AB_2564579 monoclonal
1
cited by
14
Miltenyi Biotec#130-109-641 (also 130-109-582) RRID:AB_2657159 recombinant monoclonal
1
cited by
15
BioLegend#354707 RRID:AB_2810566 monoclonal
1
cited by
16
Novus#64874AF647 RRID:AB_2915978 monoclonal
1
cited by
17
BioLegend#354705 (also 354706) RRID:AB_11218803 monoclonal
1
cited by
18
BioLegend#354702 (also 354701) RRID:AB_11218998 monoclonal
1
cited by
19
Novus#NB100-63697 RRID:AB_960722 monoclonal
0
cited by
20
Bio-Rad#MCA2392A488T RRID:AB_1101871 monoclonal
0
cited by
21
Novus#H00010462-M02 RRID:AB_1145204 monoclonal
0
cited by
22
RayBiotech#DS-MB-03809 RRID:AB_1544856 monoclonal
0
cited by
23
RayBiotech#DS-MB-03812 RRID:AB_1544857 monoclonal
0
cited by
24
RayBiotech#DS-MB-03810 RRID:AB_1544858 monoclonal
0
cited by
25
Thermo Fisher Scientific#MA1-81943 RRID:AB_2083132 monoclonal
0
cited by
이 표적 항체를 국내 공급가·납기로 확인하시겠어요? 국내 구매·견적 문의 →

CD301

이 표적에 논문에서 가장 많이 인용된 항체 순으로 정리했습니다. 각 행에서 국내 견적을 요청할 수 있습니다.

Data: Antibody Registry (SciCrunch) — RRID under CC-0; product metadata per respective source. Citation counts: Antibody Registry.